Antimalarial Drugs Market to Grow with a CAGR of 4.44% through 2030

Surge in research and development activities is expected to drive the Global Antimalarial Drugs Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Antimalarial Drugs Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Antimalarial Drugs Market stood at USD 554.20 Million in 2024 and is anticipated to grow with a CAGR of 4.44% through 2030. Initiatives taken by government based on antimalarial drugs has led to favorable market conditions for the Global Antimalarial Drugs Market. Several factors contribute to the growth of various antimalarial drugs products.

One of the primary objectives of ongoing R&D is to address the growing threat of drug-resistant malaria strains. Resistance to traditional antimalarial treatments, including chloroquine and artemisinin-based therapies, has been reported in parts of Southeast Asia and Africa. In response, researchers are developing next-generation therapies, such as triple artemisinin-based combination therapies (TACTs), to enhance treatment efficacy and delay the emergence of resistance. These efforts aim to preserve the clinical utility of existing drugs while improving patient outcomes.

One of the most significant steps taken by many national governments is the inclusion of antimalarial drugs in publicly funded healthcare programs. By subsidizing or providing these medicines free of charge through national health systems, governments have significantly improved access to treatment, especially in low- and middle-income countries where the burden of malaria remains high. These programs are often supported by international partners such as the Global Fund and the World Health Organization (WHO), ensuring sustained funding and efficient distribution of essential drugs.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Antimalarial Drugs Market”

The Global Antimalarial Drugs Market is segmented into drug type, malaria type, regional distribution, and company.

Based on Drug Type, Chloroquine have emerged as the dominating segment in the Global Antimalarial Drugs Market in 2024.  The affordability and widespread availability of chloroquine make it particularly valuable in low- and middle-income countries, where access to newer, more expensive antimalarials is often limited. Chloroquine’s stability, ease of storage, and suitability for oral administration also make it a practical choice in regions with minimal healthcare infrastructure. Its inclusion in the World Health Organization’s list of essential medicines has further reinforced its importance and global distribution.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global Antimalarial Drugs Market in 2024. Several countries in the region, including India, Indonesia, Myanmar, and Papua New Guinea, continue to report a high burden of malaria, particularly infections caused by Plasmodium falciparum and Plasmodium vivax. This persistent disease prevalence has created a strong demand for effective antimalarial therapies and accelerated public health interventions. Furthermore, national malaria control programs backed by international organizations such as the WHO, the Global Fund, and the Asia Pacific Malaria Elimination Network (APMEN) have significantly enhanced disease surveillance, diagnosis, and drug distribution efforts across the region.

Major companies operating in Global Antimalarial Drugs Market are:

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“Nanotechnology is increasingly becoming a pivotal factor in the evolution of the global antimalarial drugs market, offering innovative solutions to enhance drug efficacy, delivery, and patient outcomes. By leveraging nanoscale materials and delivery systems, pharmaceutical developers are able to improve the bioavailability and targeted release of antimalarial compounds, thereby increasing therapeutic effectiveness while minimizing side effects. Nanotechnology-enabled drug delivery platform such as nanoparticles, liposomes, and nanoemulsions allow for controlled and sustained release of active ingredients, improving treatment adherence by potentially reducing dosing frequency”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Antimalarial Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Antimalarial Drugs Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]